Adult Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment for Diffuse, Small Noncleaved-Cell / Burkitt Lymphoma
Diffuse, small, noncleaved-cell/Burkitt lymphoma typically involves younger patients and represents the most common type of pediatric NHL.Standard Treatment Options for Diffuse, Small Noncleaved-Cell/Burkitt LymphomaStandard treatment options for diffuse, small, noncleaved-cell/Burkitt lymphoma include the following:Aggressive multidrug regimens.Central nervous system (CNS) prophylaxis.Aggressive multidrug regimensStandard treatment for diffuse, small, noncleaved-cell/Burkitt lymphoma is usually with aggressive multidrug regimens similar to those used for the advanced-stage aggressive lymphomas (such as diffuse large cell).[2,3,4] In some institutions, treatment includes the use of consolidative bone marrow transplantation.[5,6] Adverse prognostic factors include bulky abdominal disease and high serum lactate dehydrogenase.Evidence (aggressive multidrug regimens):An intensive clinical trial (CLB-9251 [NCT00002494]) used aggressive combination chemotherapy patterned after that used
Adult Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment for Aggressive, Recurrent Adult NHL
Standard Treatment Options for Aggressive, Recurrent Adult NHLStandard treatment options for aggressive, recurrent adult non-Hodgkin lymphoma (NHL) include the following:Bone marrow or stem cell transplantation.Re-treatment with standard agents.Palliative radiation therapy.Bone marrow or stem cell transplantationBone marrow transplantation (BMT) is the treatment of choice for patients whose lymphoma has relapsed. Preliminary studies indicate that approximately 20% to 40% of patients will have a long-term disease-free status, but the precise percentage depends on patient selection and the specific treatment used. Preparative drug regimens have varied; some investigators also use total-body irradiation. Similar success has been achieved using autologous marrow, with or without marrow purging, and allogeneic marrow.[2,3,4,5,6]Evidence (BMT):In a prospective, randomized study, (EORTC-PARMA), 215 patients in first or second relapse of aggressive lymphoma, younger than 60 years, and
Adult Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Patient Information [NCI] - Treatment Option Overview
There are different types of treatment for patients with non-Hodgkin lymphoma. Different types of treatment are available for patients with non-Hodgkin lymphoma. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.For pregnant women with non-Hodgkin lymphoma, treatment is carefully chosen to protect the fetus. Treatment decisions are based on the mother's wishes, the stage of the non-Hodgkin lymphoma, and the age of the fetus. The treatment plan may change as the symptoms, cancer, and pregnancy change.
Adult Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - nci_ncicdr0000062707-nci-header
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Adult Non-Hodgkin Lymphoma Treatment
Adult Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment Option Overview for Adult NHL
Treatment of non-Hodgkin lymphoma (NHL) depends on the histologic type and stage. Many of the improvements in survival have been made using clinical trials (experimental therapy) that have attempted to improve on the best available accepted therapy (conventional or standard therapy). In asymptomatic patients with indolent forms of advanced NHL, treatment may be deferred until the patient becomes symptomatic as the disease progresses. When treatment is deferred, the clinical course of patients with indolent NHL varies; frequent and careful observation is required so that effective treatment can be initiated when the clinical course of the disease accelerates. Some patients have a prolonged indolent course, but others have disease that rapidly evolves into more aggressive types of NHL that require immediate treatment.Radiation techniques differ somewhat from those used in the treatment of Hodgkin lymphoma. The dose of radiation therapy usually varies from 25 Gy to 50 Gy and is
Adult Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment for Indolent, Recurrent Adult NHL
In general, treatment with standard agents rarely produces a cure in patients whose disease has relapsed. Sustained remissions after relapse can often be obtained in patients with indolent lymphomas, but relapse will usually ensue. Favorable survival after relapse has been associated with an age younger than 60 years, complete remission rather than partial remission, and duration of response longer than 1 year. Even the most favorable subset, however, has a tenfold greater mortality compared with age-adjusted U.S. population rates. Patients who experience a relapse with indolent lymphoma can often have their disease controlled with single agent or combination chemotherapy, rituximab (an anti-CD20 monoclonal antibody), lenalidomide, radiolabeled anti-CD20 monoclonal antibodies, or palliative radiation therapy.[2,3] Long-term freedom from second relapse, however, is uncommon and multiple relapses will usually occur. Patients with indolent lymphoma may experience a relapse with a
Adult Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Aggressive NHL
Aggressive non-Hodgkin lymphoma (NHL) includes the following subtypes:Diffuse large B-cell lymphoma.Mediastinal large B-cell lymphoma (primary mediastinal large B-cell lymphoma).Follicular large cell lymphoma.Anaplastic large cell lymphoma.Extranodal NK-/T-cell lymphoma.Lymphomatoid granulomatosis.Angioimmunoblastic T-cell lymphoma.Peripheral T-cell lymphoma.Enteropathy-type intestinal T-cell lymphoma.Intravascular large B-cell lymphoma (intravascular lymphomatosis).Burkitt lymphoma/diffuse small noncleaved-cell lymphoma.Lymphoblastic lymphoma.Adult T-cell leukemia/lymphoma.Mantle cell lymphoma.Polymorphic posttransplantation lymphoproliferative disorder.True histiocytic lymphoma.Primary effusion lymphoma.Diffuse Large B-cell LymphomaDiffuse large B-cell lymphoma (DLBCL) is the most common of the NHLs and comprises 30% of newly diagnosed cases. Most patients present with rapidly enlarging masses, often with both local and systemic
Adult Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment for Indolent, Stage I and Contiguous Stage II Adult NHL
Although localized presentations are uncommon in non-Hodgkin lymphoma (NHL), the goal of treatment should be to cure the disease in patients who are shown to have truly localized occurrence after undergoing appropriate staging procedures.Standard Treatment Options for Indolent, Stage I and Contiguous Stage II Adult NHLStandard treatment options for indolent, stage I and contiguous stage II adult NHL include the following:Radiation therapy.Rituximab with or without chemotherapy.Watchful waiting.Other therapies as designated for patients with advanced-stage disease.The National Lymphocare Study identified 471 patients with stage I follicular lymphoma. Of those patients, 206 were rigorously staged with a bone marrow aspirate and biopsy, and computed tomography (CT) scans or positive-emission tomography (PET-CT) scans. Nonrandomized treatments included radiation therapy (27%), rituximab-chemotherapy (R-chemotherapy) (28%), watchful waiting (17%), R-chemotherapy plus radiation therapy
Childhood Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Patient Information [NCI] - Changes to This Summary (08 / 08 / 2013)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.Changes were made to this summary to match those made to the health professional version.
Understanding Non-Hodgkin Lymphoma -- the Basics
Basic information about non-Hodgkin lymphoma from the experts at WebMD.